Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2015-07-26 Investor Presentation
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
INV104 (zafirlukast) presentation - status and milestones 10 pages 585.1KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about the development and clinical strategy of an inhaled formulation of zafirlukast, including scientific background, regulatory interactions with the FDA, collaboration with a manufacturing partner, and clinical development plans. It contains no financial statements, no audit information, no voting results, no legal proceedings, and no direct financial performance data. The content is focused on product development and strategy, typical of an investor presentation. The length (9535 characters) and the detailed nature of the content support classification as an Investor Presentation rather than a brief factsheet or a regulatory filing. There is no indication that this is an official report or announcement of a report publication, nor is it a transcript or management discussion. Therefore, the most appropriate classification is Investor Presentation (IP).
2015-07-26 English
Response to Price Query 4 pages 336.4KB
Regulatory Filings Classification · 95% confidence The document is a response letter from Invion Limited to the ASX Compliance Pty Ltd regarding a price query about unusual trading activity in the company's securities. It references Listing Rules 3.1 and 3.1A, which relate to continuous disclosure obligations for listed entities. The letter addresses whether the company is aware of any undisclosed information that could explain recent price movements and confirms compliance with listing rules. There are no financial statements, earnings data, or detailed financial analysis present. The document is a regulatory communication responding to a market compliance inquiry rather than a financial report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2015-07-12 English
Milestone update 1 page 238.3KB
Capital/Financing Update Classification · 90% confidence The document is a media announcement from Invion Limited providing an update on milestones in its drug development programs. It includes specific progress details on clinical trials and anticipated milestones but does not contain financial statements, regulatory certifications, or detailed financial data. The document is relatively short (2834 characters) and serves as an update to investors rather than a formal financial or regulatory filing. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it provides substantive content rather than just announcing a report's availability. The content aligns best with a Capital/Financing Update (CAP) as it informs investors about progress in development programs, which is typical for biotech companies updating on R&D milestones and potential value drivers.
2015-07-02 English
PhII smoking cessation - dosing complete analysis underway 2 pages 349.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX media announcement from Invion Limited about the completion of dosing in a Phase II clinical trial for a drug candidate (INV102 nadolol) related to smoking cessation and respiratory diseases. It discusses clinical trial progress, interim data, and market potential but does not contain financial statements, regulatory certifications, or detailed financial results. The document is a corporate announcement about a clinical trial milestone rather than a financial report or regulatory filing. It is not an Annual Report, Interim Report, Earnings Release, or any other financial filing. It fits best as a Regulatory Filing (RNS) because it is a general corporate announcement that does not fit other specific categories.
2015-06-28 English
Appendix 3B - lapse of unlisted share options 13 pages 500.4KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to securities issuance. It includes detailed information about the class and number of securities issued, exercise prices, expiry dates, shareholder approvals, and placement capacity calculations under ASX Listing Rules 7.1 and 7.1A. The content focuses on capital raising activities and securities issuance rather than financial results, management changes, or legal matters. Therefore, this document is best classified as a Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement but a substantive filing about capital changes.
2015-06-18 English
Appendix 3B - lapse of options issued under ESOP 13 pages 512.3KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to securities issuance. It includes detailed information about the class and number of securities issued, exercise prices, expiry dates, shareholder approvals, and placement capacity calculations under ASX Listing Rules 7.1 and 7.1A. The document does not contain financial statements, earnings data, management discussion, or audit information. Instead, it is a regulatory announcement about capital raising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement but a full regulatory filing of a capital raising event.
2015-06-16 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.